KAZN: A Promising Cancer Drug Target and Biomarker (G23254)

Target Name: KAZN

NCBI ID: G23254

KAZN: A Promising Cancer Drug Target and Biomarker

KAZN is a drug target and a biomarker that is being studied for its potential in treating various diseases, including cancer. KAZN is a small molecule inhibitor of the protein B-cell maturation antigen (BCMA), which is a protein that is expressed in the cells of many different types of cancer, including breast, ovarian, and prostate cancer.

The BCMA protein is involved in the process of cell division and growth, which is critical for the development and maintenance of cancer. By inhibiting this protein, KAZN has been shown to have anti-tumor effects in various cell models and in preclinical studies.

One of the potential benefits of KAZN is its ability to selectively target the BCMA protein, while minimizing the effects on other cell proteins. This can make it a more effective treatment option than many other drugs, which often have broader and more harmful effects on cell function.

In addition to its potential as a drug target, KAZN has also been shown to be a potential biomarker for cancer. By detecting the level of BCMA protein in cancer cells, researchers can monitor the effectiveness of KAZN and other treatments. This can be an important tool for understanding the mechanisms of cancer and for developing new, more effective treatments.

Overall, KAZN is a promising drug target and biomarker for cancer. Further research is needed to fully understand its potential and to develop safe and effective treatments.

Protein Name: Kazrin, Periplakin Interacting Protein

Functions: Component of the cornified envelope of keratinocytes. May be involved in the interplay between adherens junctions and desmosomes. The function in the nucleus is not known

More Common Targets